ArticleFrontiers in oncology2024

PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer.

Norman Fultang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.